AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28042880 — intervention group
Group type: EXPERIMENTAL
Intervention: Written information about the complications of postoperative pain
Number of subjects: 760
Study 28042880 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional pain education for nurses
Number of subjects: 760
Study 25559730 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic administration (twice daily, initiated within 10 days of burn until wound closure)
Number of subjects: 20
Study 25559730 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic administration
Number of subjects: 20
Study 25559730 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration (twice daily, initiated within 10 days of burn until wound closure)
Number of subjects: 20
Study 25559730 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 20
Study 23690087 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Management Program
Number of subjects: 104
Study 23690087 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 104
Study 21768631 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative repair using an open technique
Number of subjects: 80
Study 21768631 — intervention group
Group type: COMPARATOR
Intervention: Non-operative treatment in a cast
Number of subjects: 80
Study 17525793 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based message system presenting real-time evidence to providers
Number of subjects: 44
Study 17525793 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified intervention)
Number of subjects: 44
Study 16274054 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) with Photosense, 0.05 mg/kg, performed on day 3 after administration, using a laser at 675 nm and a light dose of 120 J/cm2
Number of subjects: 15
Study 12420854 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanic acid (2 g/200 mg)
Number of subjects: 476
Study 12420854 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime (2 g)
Number of subjects: 476
Study 9452274 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA), 500 mg, twice daily for 12 weeks
Number of subjects: 54
Study 9452274 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 8573993 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol
Number of subjects: 0
Study 1973843 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 41
Study 1973843 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 41
Study 791564 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyldopa administered once at bedtime (HS)
Number of subjects: 14
Study 791564 — intervention group
Group type: COMPARATOR
Intervention: Methyldopa administered three times daily (TID)
Number of subjects: 14
Study 30734702 — intervention group
Group type: EXPERIMENTAL
Intervention: Early enteral nutrition (EEN) - hyperproteic low in colecistokinetics diet
Number of subjects: 19
Study 30734702 — intervention group
Group type: COMPARATOR
Intervention: Control group (nothing by mouth)
Number of subjects: 19
Study 30734702 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (G1 and G2)
Number of subjects: 19
Study 26475248 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography
Number of subjects: 1189
Study 26475248 — intervention group
Group type: COMPARATOR
Intervention: Landmark
Number of subjects: 1189
Study 25300706 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin (INR 2.0‐3.5)
Number of subjects: 2305
Study 25300706 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 325 mg
Number of subjects: 2305
Study 22486342 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic endurance training (AET) - 10 weeks, 30-50 min cycling at 70%-75% maximal heart rate
Number of subjects: 102
Study 22486342 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise training (RET) - 10 weeks, 2-4 sets × 8-10 repetitions of 5-7 exercises at 70%-75% 1 repetition maximum
Number of subjects: 102
Study 22486342 — intervention group
Group type: COMPARATOR
Intervention: Control (CON) - non-exercising condition
Number of subjects: 102
Study 20460257 — intervention group
Group type: EXPERIMENTAL
Intervention: Methacholine
Number of subjects: 58
Study 20460257 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine 5'-monophosphate (AMP)
Number of subjects: 58
Study 20460257 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol
Number of subjects: 58
Study 20460257 — intervention group
Group type: EXPERIMENTAL
Intervention: Eucapnic voluntary hyperventilation (EVH)
Number of subjects: 58
Study 20460257 — intervention group
Group type: EXPERIMENTAL
Intervention: Field exercise challenge
Number of subjects: 58
Study 20460257 — intervention group
Group type: EXPERIMENTAL
Intervention: Any stimulus
Number of subjects: 58
Study 18077494 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% sodium nitroprusside (NaNP)
Number of subjects: 8
Study 18077494 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% acetylcholine chloride (ACh)
Number of subjects: 8
Study 18077494 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 min treatment
Number of subjects: 8
Study 18077494 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 min treatment
Number of subjects: 8
Study 18077494 — intervention group
Group type: COMPARATOR
Intervention: NaNP vs ACh
Number of subjects: 8
Study 15849813 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonic J-pouch anastomosis
Number of subjects: 50
Study 15849813 — intervention group
Group type: COMPARATOR
Intervention: Straight coloanal anastomosis (CAA)
Number of subjects: 50
Study 14621036 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol
Number of subjects: 30
Study 14621036 — intervention group
Group type: COMPARATOR
Intervention: Control (no esmolol)
Number of subjects: 30
Study 10919681 — intervention group
Group type: EXPERIMENTAL
Intervention: CFC pressurized metered dose inhaler (pMDI; Ventolin)
Number of subjects: 423
Study 10919681 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA 134a pMDI (Ventolin CFC-free)
Number of subjects: 423
Study 8816621 — intervention group
Group type: EXPERIMENTAL
Intervention: Luteal support with oral E2 (2 mg three times daily) and vaginal P (100 mg twice daily) starting on the day of retrieval and ET
Number of subjects: 93
Study 8816621 — intervention group
Group type: COMPARATOR
Intervention: No luteal support (control group)
Number of subjects: 93
Study 1566953 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed psychoeducational materials
Number of subjects: 0
Study 1566953 — intervention group
Group type: COMPARATOR
Intervention: Control group (no psychoeducational materials)
Number of subjects: 0
Study 4050728 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron treatment (30 mg iron as ferrous sulfate given before a meal)
Number of subjects: 291
Study 4050728 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 291
Study 31599200 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 0
Study 31599200 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab with ODYSSEY LONG TERM data
Number of subjects: 0
Study 31599200 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab with FOURIER data
Number of subjects: 0
Study 31599200 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab with FOURIER data (50% weight)
Number of subjects: 0
Study 31599200 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab with FOURIER data (10% weight)
Number of subjects: 0
Study 29377755 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Number of subjects: 658
Study 29377755 — intervention group
Group type: COMPARATOR
Intervention: Everolimus
Number of subjects: 658
Study 25840585 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic lozenge containing two strains of Lactobacillus reuteri, taken once daily for 17 months.
Number of subjects: 85
Study 25840585 — intervention group
Group type: COMPARATOR
Intervention: Placebo lozenge without active bacteria, taken once daily for 17 months.
Number of subjects: 85
Study 25840585 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (probiotic and placebo)
Number of subjects: 85
Study 24511017 — intervention group
Group type: EXPERIMENTAL
Intervention: YAP1 activation gene expression signature
Number of subjects: 267
Study 22219013 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI plus cetuximab (400 mg/m2 day 1, followed by 250 mg/m2 weekly)
Number of subjects: 100
Study 22219013 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI plus bevacizumab (5 mg/kg every 2 weeks)
Number of subjects: 100
Study 22219013 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI plus cetuximab
Number of subjects: 100
Study 22219013 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI plus bevacizumab
Number of subjects: 100
Study 20426859 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment Maneuver (RM) with CPAP of 40 cmH2O over 30 seconds
Number of subjects: 40
Study 20426859 — intervention group
Group type: COMPARATOR
Intervention: Control group (no RM)
Number of subjects: 40
Study 20426859 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 40
Study 18598605 — intervention group
Group type: EXPERIMENTAL
Intervention: Single embryo transfer (SET)
Number of subjects: 0
Study 18598605 — intervention group
Group type: COMPARATOR
Intervention: Double embryo transfer (DET)
Number of subjects: 0
Study 16283062 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive strength training exercise program
Number of subjects: 167
Study 16283062 — intervention group
Group type: COMPARATOR
Intervention: Control group (sedentary)
Number of subjects: 167
Study 12131236 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive coping intervention
Number of subjects: 90
Study 12131236 — intervention group
Group type: EXPERIMENTAL
Intervention: Expression intervention
Number of subjects: 90
Study 12131236 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study 10504181 — intervention group
Group type: EXPERIMENTAL
Intervention: Reteplase
Number of subjects: 0
Study 10504181 — intervention group
Group type: COMPARATOR
Intervention: Streptokinase
Number of subjects: 0
Study 10504181 — intervention group
Group type: COMPARATOR
Intervention: Tissue plasminogen activator
Number of subjects: 0
Study 9117477 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported education program participants
Number of subjects: 0
Study 2058557 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol (1.5 mg/kg over 10 minutes)
Number of subjects: 38
Study 2058557 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 6352951 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress management training plus relaxation imagery
Number of subjects: 34
Study 6352951 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation imagery alone
Number of subjects: 34
Study 6352951 — intervention group
Group type: COMPARATOR
Intervention: Weekly blood pressure checks
Number of subjects: 34
Study 30678553 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy
Number of subjects: 5504
Study 30678553 — intervention group
Group type: COMPARATOR
Intervention: Pembrolizumab alone
Number of subjects: 5504
Study 30678553 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Pembrolizumab plus chemotherapy)
Number of subjects: 5504
Study 26946735 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow twisting needle insertion
Number of subjects: 100
Study 26946735 — intervention group
Group type: COMPARATOR
Intervention: Tubing needle insertion
Number of subjects: 100
Study 24125846 — intervention group
Group type: EXPERIMENTAL
Intervention: PAA+/PSC+ hospitals
Number of subjects: 400000
Study 24125846 — intervention group
Group type: EXPERIMENTAL
Intervention: PAA+/PSC- hospitals
Number of subjects: 400000
Study 24125846 — intervention group
Group type: EXPERIMENTAL
Intervention: PAA-/PSC+ hospitals
Number of subjects: 400000
Study 24125846 — intervention group
Group type: COMPARATOR
Intervention: PAA-/PSC- hospitals
Number of subjects: 400000
Study 21623216 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal educational intervention
Number of subjects: 186
Study 21623216 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 186
Study 19228151 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal therapy followed by neurologist (group A)
Number of subjects: 80
Study 19228151 — intervention group
Group type: COMPARATOR
Intervention: Withdrawal therapy followed by primary care physician (group B)
Number of subjects: 80
Study 16297576 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy-rich diet (25 g soy protein, >50 mg/day isoflavones)
Number of subjects: 36
Study 16297576 — intervention group
Group type: COMPARATOR
Intervention: Soy-free diet (control diet)
Number of subjects: 36
Study 15330019 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH) combined with intermittent pneumatic compression
Number of subjects: 131
Study 15330019 — intervention group
Group type: COMPARATOR
Intervention: Low-molecular-weight heparin (LMWH) combined with graduated compression stockings
Number of subjects: 131
Study 11200857 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention (eight sessions) followed by outpatient treatment
Number of subjects: 88
Study 11200857 — intervention group
Group type: COMPARATOR
Intervention: Patients who dropped out of outpatient treatment
Number of subjects: 88
Study 9294113 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (5 to 20 mg/d)
Number of subjects: 231
Study 8112205 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEP plaster (180 mg, applied b.i.d. for 14 days)
Number of subjects: 190
Study 8112205 — intervention group
Group type: COMPARATOR
Intervention: DDA emulgel (1.16%, applied q.i.d. for 14 days)
Number of subjects: 190
Study 8112205 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 190
Study 3106210 — intervention group
Group type: EXPERIMENTAL
Intervention: High fat load (3 g/kg/day)
Number of subjects: 30
Study 3106210 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium fat dosage (1.5 g/kg/day)
Number of subjects: 30
Study 3106210 — intervention group
Group type: COMPARATOR
Intervention: Only carbohydrates (as caloric source)
Number of subjects: 30
Study 31713079 — intervention group
Group type: EXPERIMENTAL
Intervention: Planning + education
Number of subjects: 102
Study 31713079 — intervention group
Group type: COMPARATOR
Intervention: Education only
Number of subjects: 102
Study 29196184 — intervention group
Group type: EXPERIMENTAL
Intervention: Binocular iPad game prescribed for 1 hour per day (n=40)
Number of subjects: 100
Study 29196184 — intervention group
Group type: COMPARATOR
Intervention: Part-time patching of the fellow eye prescribed for 2 hours per day (n=60)
Number of subjects: 100
Study 29196184 — intervention group
Group type: COMPARATOR
Intervention: Comparison of binocular iPad game vs patching
Number of subjects: 100
Study 27382543 — intervention group
Group type: EXPERIMENTAL
Intervention: Aloe vera mouthwash
Number of subjects: 90
Study 27382543 — intervention group
Group type: COMPARATOR
Intervention: 0.2% chlorhexidine gluconate mouthwash
Number of subjects: 90
Study 27382543 — intervention group
Group type: COMPARATOR
Intervention: Placebo (flavored distilled water)
Number of subjects: 90
Study 24496312 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate (H-CHO) diet
Number of subjects: 7
Study 24496312 — intervention group
Group type: COMPARATOR
Intervention: High-fat (H-FAT) diet
Number of subjects: 7
Study 24496312 — intervention group
Group type: EXPERIMENTAL
Intervention: Feeding (after fasting)
Number of subjects: 7
Study 24496312 — intervention group
Group type: COMPARATOR
Intervention: Fasting (before feeding)
Number of subjects: 7
Study 22969068 — intervention group
Group type: EXPERIMENTAL
Intervention: Ortho-k lenses
Number of subjects: 102
Study 22969068 — intervention group
Group type: COMPARATOR
Intervention: Single-vision glasses
Number of subjects: 102
Study 20576182 — intervention group
Group type: EXPERIMENTAL
Intervention: Gang involvement at age 13 to 14
Number of subjects: 998
Study 20576182 — intervention group
Group type: EXPERIMENTAL
Intervention: Deviancy training with friends at age 16 to 17
Number of subjects: 998
Study 20576182 — intervention group
Group type: EXPERIMENTAL
Intervention: Violence by age 18 to 19
Number of subjects: 998
Study 20576182 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect and direct path between early adolescent gang involvement and later violence
Number of subjects: 998
Study 17765013 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaboxadol 10 mg
Number of subjects: 822
Study 17765013 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaboxadol 15 mg
Number of subjects: 822
Study 17765013 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 822
Study 19595361 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-PCI ECG T-wave amplitude
Number of subjects: 207
Study 19595361 — intervention group
Group type: EXPERIMENTAL
Intervention: Net decrease in T-wave amplitude during reperfusion therapy
Number of subjects: 207
Study 19595361 — intervention group
Group type: EXPERIMENTAL
Intervention: Large T-wave amplitudes in static pre- and post-PCI ECGs
Number of subjects: 207
Study 19595361 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic development of more negative T waves during PCI
Number of subjects: 207
Study 15007652 — intervention group
Group type: EXPERIMENTAL
Intervention: Limonene oxidation products (LOPs)
Number of subjects: 8
Study 15007652 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate radicals (NO(3))
Number of subjects: 8
Study 15007652 — intervention group
Group type: COMPARATOR
Intervention: Residual reactants
Number of subjects: 8
Study 15007652 — intervention group
Group type: COMPARATOR
Intervention: Clean air
Number of subjects: 8
Study 12075385 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 70
Study 12075385 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated Heparin (UH)
Number of subjects: 70
Study 9598491 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg oral sertraline
Number of subjects: 37
Study 9598491 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 9598491 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic open label treatment with sertraline
Number of subjects: 37
Study 7873461 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus pamidronate (Aredia) 45 mg intravenously every 3 weeks
Number of subjects: 295
Study 7873461 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 295
Study 7873461 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus pamidronate (Aredia)
Number of subjects: 295
Study 3285485 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate 120 mg/d plus diethylstilbestrol (DES) 0.1 to 3 mg/d
Number of subjects: 81
Study 3285485 — intervention group
Group type: COMPARATOR
Intervention: Diethylstilbestrol (DES) 0.1 to 3 mg/d
Number of subjects: 81
Study 3285485 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate plus minidose DES
Number of subjects: 81
Study 3285485 — intervention group
Group type: COMPARATOR
Intervention: Diethylstilbestrol (DES)
Number of subjects: 81
Study 11557459 — intervention group
Group type: EXPERIMENTAL
Intervention: IDV-RTV 800-100 mg
Number of subjects: 73
Study 11557459 — intervention group
Group type: EXPERIMENTAL
Intervention: IDV-RTV 800-200 mg
Number of subjects: 73
Study 11557459 — intervention group
Group type: EXPERIMENTAL
Intervention: IDV-RTV 400-400 mg
Number of subjects: 73
Study 11557459 — intervention group
Group type: COMPARATOR
Intervention: Placebo of IDV with RTV 100 mg
Number of subjects: 73
Study 11557459 — intervention group
Group type: COMPARATOR
Intervention: Placebo of IDV with RTV 200 mg
Number of subjects: 73
Study 11557459 — intervention group
Group type: COMPARATOR
Intervention: Placebo of IDV with RTV 400 mg
Number of subjects: 73
Study 11557459 — intervention group
Group type: COMPARATOR
Intervention: Placebo of both IDV and RTV
Number of subjects: 73
Study 11557459 — intervention group
Group type: EXPERIMENTAL
Intervention: IDV-RTV regimens
Number of subjects: 73
Study 31257177 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab duocarmazine (1.2 mg/kg recommended phase 2 dose)
Number of subjects: 185
Study 31257177 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab duocarmazine
Number of subjects: 185
Study 29328779 — intervention group
Group type: EXPERIMENTAL
Intervention: Coordinated Specialty Care (CSC)
Number of subjects: 0
Study 29328779 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment settings
Number of subjects: 0
Study 26881303 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic pain interventions (specific interventions not detailed in the abstract)
Number of subjects: 188
Study 24904204 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS) applied for 30 minutes once a day for 60 days.
Number of subjects: 61
Study 24904204 — intervention group
Group type: COMPARATOR
Intervention: Basic therapy (control group).
Number of subjects: 61
Study 24904204 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS).
Number of subjects: 61
Study 22980307 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 102
Study 22980307 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 102
Study 22980307 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin
Number of subjects: 102
Study 20195181 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense interval training (INT)
Number of subjects: 36
Study 20195181 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged running
Number of subjects: 36
Study 20195181 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training
Number of subjects: 36
Study 17272968 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosigne
Number of subjects: 26
Study 17272968 — intervention group
Group type: COMPARATOR
Intervention: Botox
Number of subjects: 26
Study 16033938 — intervention group
Group type: EXPERIMENTAL
Intervention: No delay in roll perturbation
Number of subjects: 19
Study 16033938 — intervention group
Group type: EXPERIMENTAL
Intervention: Short 50-ms delay in roll perturbation
Number of subjects: 19
Study 16033938 — intervention group
Group type: EXPERIMENTAL
Intervention: Long 150-ms delay in roll perturbation
Number of subjects: 19